ZA965935B - Heterocyclic compounds. - Google Patents

Heterocyclic compounds.

Info

Publication number
ZA965935B
ZA965935B ZA9605935A ZA965935A ZA965935B ZA 965935 B ZA965935 B ZA 965935B ZA 9605935 A ZA9605935 A ZA 9605935A ZA 965935 A ZA965935 A ZA 965935A ZA 965935 B ZA965935 B ZA 965935B
Authority
ZA
South Africa
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
ZA9605935A
Other languages
English (en)
Inventor
George Stuart Cockerill
Malcolm Clive Carter
Stephen Karl Mckeown
Sadie Vile
Martin John Page
Alan Thomas Hudson
Paul Barraclough
Karl Witold Franzmann
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA965935B publication Critical patent/ZA965935B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA9605935A 1995-07-13 1996-07-12 Heterocyclic compounds. ZA965935B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9514265.9A GB9514265D0 (en) 1995-07-13 1995-07-13 Hetrocyclic compounds

Publications (1)

Publication Number Publication Date
ZA965935B true ZA965935B (en) 1998-02-12

Family

ID=10777551

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9605935A ZA965935B (en) 1995-07-13 1996-07-12 Heterocyclic compounds.

Country Status (7)

Country Link
EP (1) EP0843671A1 (ja)
JP (1) JPH11508906A (ja)
AU (1) AU6613996A (ja)
GB (1) GB9514265D0 (ja)
HR (1) HRP960316A2 (ja)
WO (1) WO1997003069A1 (ja)
ZA (1) ZA965935B (ja)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (ja) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
DE69613367T2 (de) * 1995-04-27 2002-04-18 Astrazeneca Ab, Soedertaelje Chinazolin derivate
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
JP4386967B2 (ja) * 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
US6310211B1 (en) 1996-09-10 2001-10-30 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6809097B1 (en) * 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
WO1998056376A1 (en) * 1997-06-13 1998-12-17 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
WO2000010981A1 (en) * 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
DK1119567T3 (da) 1998-10-08 2005-07-25 Astrazeneca Ab Quinazolinderivater
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
AU2437900A (en) * 1999-01-20 2000-08-07 Smithkline Beecham Plc Piperidinylquinolines as protein tyrosine kinase inhibitors
AU763618B2 (en) 1999-02-10 2003-07-31 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
ATE375984T1 (de) 1999-07-07 2007-11-15 Astrazeneca Uk Ltd Chinazolin derivate
EP1192151B1 (en) 1999-07-09 2007-11-07 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
DK1212327T3 (da) 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7498335B2 (en) 2000-03-06 2009-03-03 Astrazeneca Ab Method of producing an antiangiogenic or vascular permeability reducing effect
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US7001904B1 (en) 2000-06-24 2006-02-21 Astrazeneca Ab Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases
NZ522696A (en) * 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
HUP0300721A3 (en) 2000-07-26 2006-02-28 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity, process for producing them, pharmaceutical compositions containing them and use thereof
CA2415469A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
SK2142003A3 (en) 2000-08-21 2003-07-01 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical composition comprising same and their use
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
EP1317442B1 (en) * 2000-09-11 2005-11-16 Chiron Corporation Quinolinone derivatives as tyrosine kinase inhibitors
JP2004509876A (ja) 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
WO2002030924A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
AU2002212436A1 (en) * 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
UY27225A1 (es) * 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
CA2441492C (en) * 2001-03-23 2011-08-09 Bayer Corporation Rho-kinase inhibitors
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
KR100810468B1 (ko) * 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
BRPI0215312B8 (pt) 2001-12-24 2021-05-25 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
EP1470121B1 (en) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
DE60318177T2 (de) 2002-01-23 2008-10-09 Bayer Pharmaceuticals Corp., West Haven Rho-kinase inhibitoren
EP2181996A1 (en) 2002-01-29 2010-05-05 Glaxo Group Limited Aminopiperidine derivatives
EP1470131A2 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
RU2365588C2 (ru) * 2002-02-01 2009-08-27 Астразенека Аб Хиназолиновые соединения
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ATE429230T1 (de) 2002-07-09 2009-05-15 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP4613130B2 (ja) 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
ES2298563T3 (es) 2002-10-09 2008-05-16 Critical Outcome Technologies, Inc. Inhibidores de proteinas tirosina cinasas.
US7622592B2 (en) * 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
JP4593464B2 (ja) * 2002-11-04 2010-12-08 アストラゼネカ アクチボラグ Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体
CN100354278C (zh) * 2002-11-04 2007-12-12 阿斯利康(瑞典)有限公司 作为src酪氨酸激酶抑制剂的喹唑啉衍生物
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
US7429597B2 (en) 2002-12-23 2008-09-30 Boehringer Ingelheim Pharma Gmbh & Co., Kg Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
DE10260730A1 (de) 2002-12-23 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte stickstoffhaltige Heterobicyclen, deren Herstellung und deren Verwendung als Arzneimittel
SI1847539T1 (sl) 2002-12-24 2010-01-29 Astrazeneca Ab Kinazolinski derivati
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
UA82577C2 (en) 2003-12-23 2008-04-25 Пфайзер Инк. Quinoline derivatives
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
CN1933839A (zh) 2004-01-23 2007-03-21 安进公司 化合物和使用方法
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
WO2005075439A1 (en) 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
CA2556872C (en) 2004-02-20 2015-05-12 Chiron Corporation Modulation of inflammatory and metastatic processes
JP4205757B2 (ja) 2004-05-06 2009-01-07 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ４−フェニルアミノ−キナゾリン−６−イル−アミド
WO2005120509A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
MXPA06014125A (es) * 2004-06-04 2007-01-31 Astrazeneca Ab Derivados de quinazolina en la forma de cinasas de tirosina de receptor erbb.
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
US8153643B2 (en) * 2004-10-12 2012-04-10 Astrazeneca Ab Quinazoline derivatives
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
ATE501148T1 (de) 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
US7358256B2 (en) 2005-03-28 2008-04-15 Bristol-Myers Squibb Company ATP competitive kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
KR101319122B1 (ko) 2005-05-13 2013-10-23 노파르티스 아게 약물 저항성 암을 치료하는 방법
ES2376347T3 (es) 2005-05-17 2012-03-13 Novartis Ag Métodos para sintetizar compuestos heteroc�?clicos.
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
CN101263125A (zh) * 2005-07-15 2008-09-10 先灵公司 用于癌症治疗的喹唑啉衍生物
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
WO2007034144A1 (en) 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
EP2295432A1 (en) 2006-02-10 2011-03-16 TransTech Pharma Inc. Process for the preparation of aminobenzimidazole derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
CN101443009A (zh) 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
KR20090116782A (ko) 2007-02-06 2009-11-11 베링거 인겔하임 인터내셔날 게엠베하 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법
WO2009037343A1 (en) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
EA018716B1 (ru) 2007-10-29 2013-10-30 Натко Фарма Лимитед Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
US7795254B2 (en) 2007-10-29 2010-09-14 Amgen Inc. Benzomorpholine derivatives and methods of use
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
KR20100111291A (ko) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MY160243A (en) 2009-09-03 2017-02-28 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
WO2012016001A1 (en) * 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
RU2013144571A (ru) 2011-03-04 2015-04-10 Ньюджен Терапьютикс, Инк. Алинзамещенные хиназолины и способы их применения
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102942561A (zh) * 2012-11-06 2013-02-27 深圳海王药业有限公司 4-氨基喹唑啉杂环化合物及其用途
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
CN105102450B (zh) 2013-04-04 2018-03-09 詹森药业有限公司 作为PERK抑制剂的N‑(2，3‑二氢‑1H‑吡咯并[2，3‑b]吡啶‑5‑基)‑4‑喹唑啉胺和N‑(2，3‑二氢‑1H‑吲哚‑5‑基)‑4‑喹唑啉胺衍生物
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
RS56362B1 (sr) 2013-09-16 2017-12-29 Astrazeneca Ab Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MA39838B1 (fr) * 2014-04-04 2019-05-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
SI3524595T1 (sl) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistosti in postopek njegove proizvodnje
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104725364B (zh) * 2015-03-12 2017-09-15 江苏省中国科学院植物研究所 6,7‑二甲氧基‑喹唑啉‑4‑胺衍生物、其制备方法及医药用途
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
CN106045980B (zh) * 2016-06-03 2017-11-03 江苏开放大学 一种喹唑啉衍生物及其制备方法
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
ES2888298T3 (es) 2017-04-27 2022-01-03 Astrazeneca Ab Compuestos de C5-anilinoquinazolina y su uso en el tratamiento de cáncer
WO2018197643A1 (en) * 2017-04-27 2018-11-01 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer
AU2018341454B2 (en) * 2017-09-26 2023-09-28 The Regents Of The University Of California Compositions and methods for treating cancer
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
TW321649B (ja) * 1994-11-12 1997-12-01 Zeneca Ltd

Also Published As

Publication number Publication date
AU6613996A (en) 1997-02-10
EP0843671A1 (en) 1998-05-27
WO1997003069A1 (en) 1997-01-30
GB9514265D0 (en) 1995-09-13
HRP960316A2 (en) 1998-02-28
JPH11508906A (ja) 1999-08-03

Similar Documents

Publication Publication Date Title
EG25227A (en) Heterocyclic compounds.
ZA965935B (en) Heterocyclic compounds.
EG24195A (en) Heterocyclic compounds
ZA9610020B (en) Heterocyclic compounds
ZA97912B (en) Heterocyclic compounds.
GB9512697D0 (en) Heterocyclic compounds
ZA961444B (en) Pyrazolylbenzoyl derivatives.
GB9518552D0 (en) New heterocyclic compounds
ZA965505B (en) Novel compounds.
PL322722A1 (en) Novel heterocyclic compounds
ZA961449B (en) Isoxazolylbenzoyl derivatives.
GB9504361D0 (en) Heterocyclic compounds
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
ZA979617B (en) Novel heterocyclic compounds.
ZA967741B (en) Diarylalkenylamine derivatives.
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA964560B (en) Anit-viral compounds.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
PL325637A1 (en) Novel heterocyclic compounds
ZA964034B (en) N-aminopyridone derivatives.
AU1542295A (en) Heterocyclic compounds
ZA962734B (en) Heterocyclic compounds
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA967934B (en) Heterocyclic compounds.
ZA966126B (en) Heterocyclic compounds.